0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Vasculitic Neuropathy in a Patient With Hereditary C1 Inhibitor Deficiency FREE

Yusuke Yakushiji, MD; Haruo Mizuta, MD; Kazuhiro Kurohara, MD; Hiroyuki Onoue, MD; Ryuichiro Okada, MD; Toshiro Yoshimura, MD; Yasuo Kuroda, MD
[+] Author Affiliations

Author Affiliations: Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga (Drs Yakushiji, Mizuta, Kurohara, Onoue, Okada, and Kuroda); and Department of Physical Therapy, Nagasaki University School of Health Sciences, Nagasaki (Dr Yoshimura), Japan.


Arch Neurol. 2007;64(5):731-733. doi:10.1001/archneur.64.5.731.
Text Size: A A A
Published online

Objective  To report the clinical, pathological, and mutational features of hereditary C1 inhibitor (C1INH) deficiency as a cause of isolated vasculitic neuropathy.

Patient  A 35-year-old woman with sensorimotor mononeuritis multiplex and facial palsy.

Results  The sural nerve biopsy results showed a decrease of myelinated fibers with axonal degeneration and severe hypersensitivity vasculitis, with deposition of C1q on vessel walls. Mutational analysis of the C1INH gene found a new mutation, a heterozygous 2–base pair deletion in exon 8. The patient was treated with plasmapheresis and intravenous methylprednisolone, followed by oral prednisolone, which resulted in marked improvement.

Conclusion  Hereditary C1INH deficiency should be included in the differential diagnosis of nonsystemic vasculitis neuropathy.

Figures in this Article

Hereditary C1 inhibitor (C1INH) deficiency is caused by mutations of the C1INH gene and shows an autosomal dominant trait.13 The clinical manifestation, if present, is mostly angioedema4,5 and, to our knowledge, the association of neuropathy has never been reported in patients with the condition. Herein, we report a case of hereditary C1INH deficiency presenting with nonsystemic vasculitic neuropathy.

A 35-year-old woman was referred to us for the evaluation of numbness and weakness of all 4 extremities. Two months previously, she had first noticed numbness over the lateral half of the dorsum of her left leg and foot. Two weeks later, similar paresthesia developed on the lateral half of the dorsum of her right leg and foot. She subsequently noticed weakness of both lower limbs, followed by numbness and weakness of both hands. These symptoms deteriorated rapidly during the following month. She had no systemic symptoms, such as fever, weight loss, or arthralgia.

According to her medical history, she had developed a butterfly rash at the age of 17 years. She visited the section of rheumatology of our hospital at the age of 25 years for evaluation of the butterfly rash and was diagnosed as having possible systemic lupus erythematosus (SLE), because she met only 3 items of the SLE diagnostic criteria: increased antinuclear antibody titer (level, 640; normal level, <40), increased anti–double-stranded DNA antibody titer (level, 58.5 arbitrary units per milliliter; normal level, <25.0 arbitrary units per milliliter), and a butterfly rash. On this occasion, low levels of serum C4 (level, <1 mg/dL; normal level, 15-40 mg/dL) and total CH50 hemolytic activity (level, 2 U/mL; normal level, 30-55 U/mL) were found. She, however, remained in good health without treatment until the development of her current neurological symptoms. There was no family history of SLE or angioedema.

The results of a general physical examination were normal, except for the scar of a butterfly rash on her face. A neurological examination showed flaccid quadriparesis with distal predominance, bilateral absence of the Achilles tendon reflexes, and asymmetric impairment of all sensory modalities on the distal parts of all limbs. Her grasping power was 0 kg on the right side and 3 kg on the left side. She was unable to stand and walk. Soon after admission, left-sided facial palsy also developed.

The results of routine laboratory studies, including urinalysis, complete blood cell counts, liver function tests, and serum electrolyte, serum urea nitrogen, fasting serum glucose, and C-reactive protein levels, were normal. Serologic test results for syphilis were negative. Her serum IgG level increased to 2780 mg/dL (normal, 850-1770 mg/dL), but her IgA and IgM levels were normal. The titers of antinuclear antibody decreased to 160 arbitrary units per milliliter, and the titer of anti–double-stranded DNA antibody also decreased to 36 arbitrary units per milliliter. Antibodies against U1RNP, Sm antigens, SS-A/Ro, SS-B/La, myeloperoxidase antineutrophil cytoplasmic antibody, proteinase 3 antineutrophil cytoplasmic antibody, single-stranded DNA, and cardiolipin were negative. Levels of complements were as follows: C1q, undetectable level; C1r, 20.1% (normal level, 40%-140%); C1s, 21.4% (normal level, 45%-130%); C2, undetectable level; C3, 70 mg/dL (normal level, 80-160 mg/dL); C4, 1 mg/dL (normal level, 15-40 mg/dL); and total CH50 hemolytic activity, 2 U/mL (normal level, 30-55 U/mL). The plasma level of C1INH was less than 2 mg/dL (normal, 10-25 mg/dL), and the C1INH activity was less than 25% (normal level, 80%-125%). The cerebrospinal fluid showed a lymphocyte count of 3.0 × 10−3/μL, a total protein level of 1.18 × 10−1 g/dL (normal level, <4.0 × 10−2 g/dL), an IgG level of 32.9 mg/dL (normal level, 1-4 mg/dL), and an IgG index of 0.75 (normal index, <0.70). The results of nerve conduction studies on 6 peripheral nerves confirmed a diagnosis of sensorimotor axonal mononeuritis multiplex. Ischemic lesions or contrast enhancement were not found on magnetic resonance images of the brain and spinal cord.

A simultaneous biopsy of the right sural nerve and adjacent peroneus brevis muscle was performed. The sural nerve was grossly enlarged. Microscopically, vasculitis consisting of a heavy extravascular infiltrate of lymphocytes associated with capillary proliferation was observed (Figure 1A). However, hypersensitivity vasculitis was not found in the adjacent muscle specimens (Figure 1B). On immunofluorescence, almost all the vessels, including proliferating capillaries, were strongly positive on anti-C1q staining (Figure 2A). A few vessels were also positive on anti-IgG staining (Figure 2B). A histogram of epon-embedded preparations showed a decrease in the myelinated fiber density, and teased nerve preparations showed axonal degeneration.

Place holder to copy figure label and caption
Figure 1.

Pathological features of nerve (A) and muscle (B) biopsy specimens. In A, the biopsy specimen of the right sural nerve shows vasculitis, consisting of an extravascular infiltration of lymphocytes associated with capillary proliferation (arrows) (hematoxylin-eosin, original magnification ×40). In B, no inflammation and no vasculitis were found in the muscle (hematoxylin-eosin); the bar indicates 100 μm.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Immunofluorescence staining of the sural nerve biopsy specimen: on immunofluorescence, almost all the vessels, including proliferating capillaries, were strongly stained with anti–C1q antibody (arrows) (A), but only large arterioles were stained with anti–IgG antibody (arrowheads) (B).

Graphic Jump Location

Lowered serum C1INH levels and decreased C1INH activity were also found in our patient's mother and sister. This led us to suspect hereditary C1INH deficiency. After obtaining informed consent, a mutation analysis was performed on the patient and her sister. We found a heterozygous 2–base pair deletion (17925_17926 del GA) in exon 8 of the C1INH gene (Figure 3), causing a frameshift at 451 glutamic acid of C1INH, which had not yet been reported on an online register that lists all published mutations of the C1INH gene (available at: http://hae.enzim.hu%/).

Place holder to copy figure label and caption
Figure 3.

Mutation analysis of the C1 inhibitor (C1INH) gene, showing a heterozygous 2–base pair deletion (17925_17926 del GA) in exon 8 of the C1INH gene: the sequence of exon 8 in a normal allele is shown (the dotted line reveals 17925_17926 GA) (A) and the sequence of exon 8 in a mutated allele is shown (the arrow reveals 17925_17926 del GA) (B).

Graphic Jump Location

After the diagnosis, the patient was treated with plasmapheresis and intravenous methylprednisolone, 1 g/d for 3 days, followed by oral prednisolone, 60 mg/d. Her muscle strength markedly improved, and she returned to work 1 year later.

To our knowledge, the development of vasculitic neuropathy and a mutation of 17925_17926 del GA in the C1INH gene have never been reported in those with hereditary C1INH deficiency. The C1INH deficiency might cause SLE-like illness,6 and our patient had a history of SLE-like illness. However, vasculitic neuropathy in our patient seems not to be caused by SLE, because we could find no clinical or laboratory findings showing that the patient's SLE had worsened during the rapid progression of her neuropathy, indicating that hereditary C1INH deficiency was directly involved in the development of vasculitic neuropathy in our patient. The relation of a new mutation in the C1INH gene with the development of vasculitic neuropathy in our patient is obscure, because little correlation has been observed between the clinical phenotype and the mutational genotype in hereditary C1INH deficiency14 and because only our patient developed neurological symptoms among family members having the same C1INH gene mutation.

C1INH is a serine protease inhibitor possessing a variety of biological functions.24 C1INH regulates the activation of the complement and contact systems. Following the activation of C1 by an immune complex, C1INH controls activation of the classic complement pathway via the inactivation of 2 proteases (C1r and C1s).14 C1INH suppresses the contact system via inactivation of plasma kallikrein and factor XIIa, which prevents the excessive generation of bradykinin, maintains the endothelial barrier, and modulates vascular permeability.13,7 In addition, C1INH was shown to inhibit selectin-mediated leukocyte-endothelial cell adhesion.8 In our patient, the serum complement profiles and the pathological features of the sural nerve showed severe hypersensitivity vasculitis and dense deposits of C1q on vessel walls, confirming that the activation of the classic complement pathway by C1INH deficiency caused hypersensitivity vasculitic neuropathy.

Our patient presented only with symptoms of neuropathy on and during admission. Ischemic lesions and contrast enhancement were not observed on magnetic resonance imaging of the brain and spinal cord. A simultaneous biopsy of the sural nerve and adjacent peroneus brevis muscle showed that hypersensitivity vasculitis was present only in the peripheral nerve compartment. These findings suggest that vasculitis was confined to the peripheral nervous system in our patient. Thus, our case indicates that hereditary C1INH deficiency might involve the nervous system without systemic manifestations and, therefore, it should be included in the differential diagnosis of nonsystemic vasculitis neuropathy.

Correspondence: Haruo Mizuta, MD, Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga 849-8501, Japan (mizutah@cc.saga-u.ac.jp).

Accepted for Publication: November 9, 2006.

Author Contributions:Study concept and design: Yakushiji, Mizuta, Kurohara, and Kuroda. Acquisition of data: Yakushiji, Mizuta, and Kurohara. Analysis and interpretation of data: Yakushiji, Mizuta, Kurohara, Onoue, Okada, and Yoshimura. Drafting of the manuscript: Yakushiji and Kurohara. Critical revision of the manuscript for important intellectual content: Mizuta, Onoue, Okada, Yoshimura, and Kuroda. Administrative, technical, and material support: Mizuta and Yoshimura. Study supervision: Kurohara and Kuroda.

Financial Disclosure: None reported.

Gompels  MMLock  RJAbinun  M  et al.  C1 inhibitor: consensus document. Clin Exp Immunol 2005;139379- 394
PubMed
Cicardi  MZingale  LZanichelli  APappalardo  ECicardi  B C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005;27286- 298
PubMed
Rosen  FSDavis  AE  Jr Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol 2005;19251- 261
PubMed
Davis  AE  Jr The pathophysiology of hereditary angioedema. Clin Immunol 2005;1143- 9
PubMed
Bork  KMeng  GStaubach  PHardt  J Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119267- 274
PubMed
Koide  MShirahama  STokura  YTakigawa  MHayakawa  MFurukawa  F Lupus erythematosus associated with C1 inhibitor deficiency. J Dermatol 2002;29503- 507
PubMed
Han  EDMacFarlane  RCMulligan  ANScafidi  JDavis  AE  III Increased vascular permeability in C1 inhibitor–deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;1091057- 1063
PubMed
Cai  SDole  VSBergmeier  W  et al.  A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005;1746462- 6466
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Pathological features of nerve (A) and muscle (B) biopsy specimens. In A, the biopsy specimen of the right sural nerve shows vasculitis, consisting of an extravascular infiltration of lymphocytes associated with capillary proliferation (arrows) (hematoxylin-eosin, original magnification ×40). In B, no inflammation and no vasculitis were found in the muscle (hematoxylin-eosin); the bar indicates 100 μm.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Immunofluorescence staining of the sural nerve biopsy specimen: on immunofluorescence, almost all the vessels, including proliferating capillaries, were strongly stained with anti–C1q antibody (arrows) (A), but only large arterioles were stained with anti–IgG antibody (arrowheads) (B).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Mutation analysis of the C1 inhibitor (C1INH) gene, showing a heterozygous 2–base pair deletion (17925_17926 del GA) in exon 8 of the C1INH gene: the sequence of exon 8 in a normal allele is shown (the dotted line reveals 17925_17926 GA) (A) and the sequence of exon 8 in a mutated allele is shown (the arrow reveals 17925_17926 del GA) (B).

Graphic Jump Location

Tables

References

Gompels  MMLock  RJAbinun  M  et al.  C1 inhibitor: consensus document. Clin Exp Immunol 2005;139379- 394
PubMed
Cicardi  MZingale  LZanichelli  APappalardo  ECicardi  B C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005;27286- 298
PubMed
Rosen  FSDavis  AE  Jr Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol 2005;19251- 261
PubMed
Davis  AE  Jr The pathophysiology of hereditary angioedema. Clin Immunol 2005;1143- 9
PubMed
Bork  KMeng  GStaubach  PHardt  J Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119267- 274
PubMed
Koide  MShirahama  STokura  YTakigawa  MHayakawa  MFurukawa  F Lupus erythematosus associated with C1 inhibitor deficiency. J Dermatol 2002;29503- 507
PubMed
Han  EDMacFarlane  RCMulligan  ANScafidi  JDavis  AE  III Increased vascular permeability in C1 inhibitor–deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;1091057- 1063
PubMed
Cai  SDole  VSBergmeier  W  et al.  A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005;1746462- 6466
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics